A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

The Latest in Gene Therapy Research

Posted by | 3:08pm on Wednesday, May 8, 2013
The Forever Fix: Gene Therapy and the Boy Who Saved It

In November 2012, for the first time in the Western world, a gene therapy was approved for sale 

Gene therapy was the topic at the Healthcare Businesswomen’s Association event on April 30 with Ricki Lewis, PhD. The crowd was captivated as Dr. Lewis detailed the history of gene therapy as told in her book The Forever Fix: Gene Therapy and the Boy Who Saved It. She made the science come to life by sharing stories of individual families.

At its simplest, gene therapy consists of transplanting normal or working genes to replace missing or defective genes in order to correct genetic disorders. The difficulty is getting the working genes into the body and to the place where they are needed without causing unintended side effects. Viruses are currently used. Dr. Lewis gave the analogy of Federal Express: viruses are delivery systems for genes.

Commercially approved gene therapy
In November 2012, for the first time in the Western world, a gene therapy was approved for sale. The European Commission approved alipogene tiparvovec (Glybera®) to treat adult patients with the rare genetic disorder familial lipoprotein lipase deficiency. It is expected to be approved soon in the US.

A variety of clinical trials are currently being run by companies ranging from large pharmaceutical companies, such as GSK,  to start-ups focusing on gene therapy, such as Bluebird Bio. These trials are investigating a variety of rare diseases including: severe primary immunodeficiency, hemophilia, adrenoleukodystrophy and beta thalassemia.

The most recent story to make headlines was the promising results presented at The American Society of Hematology by University of Pennsylvania researchers studying acute lymphoblastic leukemia. Novartis is supporting these efforts. Study participant Emma Whitehead’s complete remission from disease captured media attention.

The future looks bright
“I think that gene therapy will be one of many new approaches to treating disease based on knowledge of our genome sequences and gene expression patterns,” said Dr. Lewis. “It will be especially helpful in treating disease early in the course of pathogenesis; or even before it starts, before cells have been destroyed. Once cells are destroyed; stem cells are a better strategy.”

In this video Dr. Lewis describes gene therapy and how she came up with the title of her book.

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

One Pingback/Trackback

    09 May 2013 at 9:05am
    The latest in #genetherapy research featuring @rickilewis http://t.co/JEFVipnZgd cc @hbagp @hbanet ...
  • Eileen O'Brien (@EileenOBrien)
Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com